查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1447173

藥物混懸劑市場：按類型、按適應症、按最終用戶、按分銷管道：2023-2032 年全球機會分析和行業預測

Pharmaceutical Suspension Market By Type, By Indication, By End User, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 315 Pages | 商品交期: 2-3個工作天內

價格

2022年藥物混懸劑市值為555億美元，預計2023年至2032年複合年成長率為4.2%，到2032年達到838億美元。

藥物混懸劑市場-IMG1

藥物混懸劑是一種在液體介質中具有精細分散的固體顆粒的液體製劑，通常用於口服或腸胃外給藥。這些懸浮液提供了多功能的藥物傳輸系統，可提高難溶性藥物的穩定性和生物有效性。固體顆粒通常是難溶性藥物，均勻分散在液相中以防止沉澱。藥物混懸劑具有諸如易於給藥、提高患者依從性以及劑量調整靈活性等優點。它在輸送具有不同溶解度的藥物並確保治療效果方面發揮著重要作用。該配方的適應性使其成為各種醫療條件的合適選擇，有助於其在製藥行業的廣泛應用。

由於感染疾病、癌症和神經系統疾病等慢性病盛行率的上升，藥物混懸劑市場呈現顯著成長。根據美國癌症協會的數據，2023 年光是美國就有 1,958,310 例新癌症病例。同樣，根據美國國立衛生研究院的數據，全球整體超過 40% 的人患有胃腸道併發症。疾病的迅速增加凸顯了對有效藥物輸送系統的需求。藥物混懸劑為藥物給藥提供了一個多功能平台，並在市場中發揮關鍵作用。

隨著此類慢性疾病變得更加普遍，由於需要滿足與此類健康挑戰相關的複雜治療要求，藥物混懸液市場有望擴大。然而，由於穩定性和溶解度問題，並非所有藥物都可以透過懸浮液有效遞送，這限制了藥物相容性並阻礙了市場成長。此外，製造複雜性，包括需要專門的設備和工藝，增加了生產成本並限制了製造商的數量，從而限制了市場准入和承受能力。

藥物混懸劑市場分為類型、適應症、最終用戶、分銷管道和地區。依類型分類，市場分為口服製劑、腸胃外製劑等。依適應症分為感染疾病、癌症、腸胃疾病、神經系統疾病等。依最終用戶分類，市場分為醫院/診所、居家醫療機構等。按分銷管道分類，市場分為醫院藥房、藥局/零售藥房和線上提供者。按地區分類，對北美、歐洲、亞太地區和拉丁美洲地區市場進行了分析。

相關人員的主要利益

  • 該報告提供了 2022 年至 2032 年藥物混懸劑市場分析的細分市場、當前趨勢、估計/趨勢分析和動態的定量分析，並確定了一般藥物混懸液市場機會。
  • 我們提供市場研究以及與市場促進因素、市場限制和市場機會相關的資訊。
  • 波特的五力分析強調買家和供應商幫助相關人員做出利潤驅動的商業決策並加強供應商和買家網路的潛力。
  • 對藥物混懸液市場細分的詳細分析有助於識別市場機會。
  • 每個地區的主要國家都根據其對全球市場的收益貢獻繪製了地圖。
  • 市場參與者定位有助於對標，並可以清楚了解市場參與者的當前地位。
  • 它還包括對區域和全球藥物混懸劑市場趨勢、主要企業、細分市場、應用領域和市場成長策略的分析。

可使用此報告進行客製化（需要額外費用和時間表）

  • 科技趨勢分析
  • 國家、區域和全球各級的患者/流行病學資料
  • 監管指引
  • 針對客戶興趣的其他公司簡介
  • 公司簡介的擴充列表
  • 歷史市場資料
  • SWOT分析

目錄

第1章簡介

第 2 章執行摘要

第3章市場概況

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資機會
  • 波特五力分析
  • 市場動態
    • 促進因素
      • 藥物開發活動增加
      • 患者對混懸液配方的依從性
      • 學名藥的可用性
    • 抑制因素
      • 藥物相容性限制
    • 機會
      • 加大舉措拓展市場

第4章 藥物混懸液市場：依類型

  • 概述
  • 口服劑
  • 注射劑
  • 其他

第5章 藥物混懸液市場：依適應症分類

  • 概述
  • 感染疾病
  • 癌症
  • 消化器官
  • 神經
  • 其他

第6章 藥物混懸液市場：依最終使用者分類

  • 概述
  • 醫院和診所
  • 居家醫療
  • 其他

第7章 藥物混懸液市場：依分銷管道

  • 概述
  • 醫院藥房
  • 藥局和零售藥局
  • 線上提供者

第8章 藥物混懸液市場：依地區

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 其他
  • 拉丁美洲/中東/非洲
    • 巴西
    • 沙烏地阿拉伯
    • 南非
    • 其他

第9章 競爭形勢

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 2022年主要企業定位

第10章 公司簡介

  • Pfizer Inc.
  • Merck & Co., Inc.
  • AstraZeneca plc
  • Eli Lilly and Company.
  • Bayer AG
  • Sanofi
  • Lupin
  • Glenmark Pharmaceuticals Limited
  • Novartis AG
  • Teva Pharmaceutical Industries Limited
Product Code: A12351

The The pharmaceutical suspension market was valued at $55.5 billion in 2022, and is estimated to reach $83.8 billion by 2032, growing at a CAGR of 4.2% from 2023 to 2032.

Pharmaceutical Suspension Market - IMG1

Pharmaceutical suspensions are liquid formulations comprising finely dispersed solid particles in a liquid medium, often for oral or parenteral administration. These suspensions provide a versatile drug delivery system allowing for enhanced stability and bioavailability of poorly soluble drugs. The solid particles, typically insoluble drugs, are uniformly dispersed in the liquid phase, preventing settling. Pharmaceutical suspensions offer advantages such as ease of administration, improved patient compliance, and flexibility in dosage adjustments. They play a crucial role in delivering drugs with variable solubility profiles, ensuring therapeutic efficacy. The formulation's adaptability makes it a preferred choice for diverse medical conditions, contributing to its widespread use in the pharmaceutical industry.

The pharmaceutical suspensions market is witnessing significant growth, attributed to rise in prevalence of chronic conditions such as infectious diseases, cancer, and neurological disorders. According to the American Cancer Society, in 2023, the U.S. alone accounted for 1,958,310 new cancer cases. Similarly, according to the National Institutes of Health, more than 40% of people globally suffer from gastrointestinal complications. This surge in disease incidence emphasizes the critical need for effective drug delivery systems. Pharmaceutical suspensions play a pivotal role in the market, offering a versatile platform for administering medications.

As these chronic conditions become more pervasive, the pharmaceutical suspensions market is poised for expansion, driven by the imperative to address the complex treatment requirements associated with such health challenges. However, limited drug compatibility hinders the market growth as not all medications are effectively delivered through suspensions due to stability and solubility issues. In addition, manufacturing complexities such as requiring specialized equipment and processes, increase production costs and restrict the number of manufacturers, limiting market accessibility and affordability.

The pharmaceutical suspension market is segmented into type, indication, end user, distribution channel, and region. On the basis of type, the market is segmented into oral, parenteral, and others. On the basis of indication, it is segmented into infectious diseases, cancer, gastrointestinal, neurological, and others. On the basis of end user, the market is segmented into hospitals and clinics, home care settings, and others. On the basis of distribution channel, the market is segmented into hospital pharmacies, drug store and retail pharmacies, and online providers. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major players that operate in the pharmaceutical suspension market include Pfizer Inc., Merck & Co., Inc., AstraZeneca plc, Eli Lilly and Company, Bayer AG, Sanofi, Lupin, Glenmark Pharmaceuticals Limited, Novartis AG, and Teva Pharmaceutical Industries Limited. The key players have adopted key strategies such as product approval and collaboration to expand their product portfolio.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the pharmaceutical suspension market analysis from 2022 to 2032 to identify the prevailing pharmaceutical suspension market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the pharmaceutical suspension market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global pharmaceutical suspension market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Technology Trend Analysis
  • Patient/epidemiology data at country, region, global level
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Expanded list for Company Profiles
  • Historic market data
  • SWOT Analysis

Key Market Segments

By Type

  • Oral
  • Parenteral
  • Others

By Indication

  • Infectious Diseases
  • Cancer
  • Gastrointestinal
  • Neurological
  • Others

By End User

  • Hospitals and Clinics
  • Home Care Settings
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Drug Store and Retail Pharmacies
  • Online Providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Pfizer Inc.
    • AstraZeneca plc
    • Eli Lilly and Company.
    • Sanofi
    • Lupin
    • Novartis AG
    • Teva Pharmaceutical Industries Limited
    • Merck & Co., Inc.
    • Bayer AG
    • Glenmark Pharmaceuticals Limited

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. High bargaining power of suppliers
    • 3.3.2. Moderate threat of new entrants
    • 3.3.3. High threat of substitutes
    • 3.3.4. Moderate intensity of rivalry
    • 3.3.5. Moderate bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increased Drug Development Activities
      • 3.4.1.2. Patient Compliance offered by pharmaceutical suspensions
      • 3.4.1.3. Availability of generic pharmaceutical suspensions
    • 3.4.2. Restraints
      • 3.4.2.1. Limited drug compatibility
    • 3.4.3. Opportunities
      • 3.4.3.1. Growing initiatives for market expansion

CHAPTER 4: PHARMACEUTICAL SUSPENSION MARKET, BY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Oral
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Parenteral
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Others
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Infectious Diseases
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Cancer
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Gastrointestinal
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Neurological
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country
  • 5.6. Others
    • 5.6.1. Key market trends, growth factors and opportunities
    • 5.6.2. Market size and forecast, by region
    • 5.6.3. Market share analysis by country

CHAPTER 6: PHARMACEUTICAL SUSPENSION MARKET, BY END USER

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospitals and Clinics
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Home Care Settings
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Others
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL

  • 7.1. Overview
    • 7.1.1. Market size and forecast
  • 7.2. Hospital Pharmacies
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by region
    • 7.2.3. Market share analysis by country
  • 7.3. Drug Store and Retail Pharmacies
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by region
    • 7.3.3. Market share analysis by country
  • 7.4. Online Providers
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by region
    • 7.4.3. Market share analysis by country

CHAPTER 8: PHARMACEUTICAL SUSPENSION MARKET, BY REGION

  • 8.1. Overview
    • 8.1.1. Market size and forecast By Region
  • 8.2. North America
    • 8.2.1. Key market trends, growth factors and opportunities
    • 8.2.2. Market size and forecast, by Type
    • 8.2.3. Market size and forecast, by Indication
    • 8.2.4. Market size and forecast, by End User
    • 8.2.5. Market size and forecast, by Distribution Channel
    • 8.2.6. Market size and forecast, by country
      • 8.2.6.1. U.S.
      • 8.2.6.1.1. Market size and forecast, by Type
      • 8.2.6.1.2. Market size and forecast, by Indication
      • 8.2.6.1.3. Market size and forecast, by End User
      • 8.2.6.1.4. Market size and forecast, by Distribution Channel
      • 8.2.6.2. Canada
      • 8.2.6.2.1. Market size and forecast, by Type
      • 8.2.6.2.2. Market size and forecast, by Indication
      • 8.2.6.2.3. Market size and forecast, by End User
      • 8.2.6.2.4. Market size and forecast, by Distribution Channel
      • 8.2.6.3. Mexico
      • 8.2.6.3.1. Market size and forecast, by Type
      • 8.2.6.3.2. Market size and forecast, by Indication
      • 8.2.6.3.3. Market size and forecast, by End User
      • 8.2.6.3.4. Market size and forecast, by Distribution Channel
  • 8.3. Europe
    • 8.3.1. Key market trends, growth factors and opportunities
    • 8.3.2. Market size and forecast, by Type
    • 8.3.3. Market size and forecast, by Indication
    • 8.3.4. Market size and forecast, by End User
    • 8.3.5. Market size and forecast, by Distribution Channel
    • 8.3.6. Market size and forecast, by country
      • 8.3.6.1. Germany
      • 8.3.6.1.1. Market size and forecast, by Type
      • 8.3.6.1.2. Market size and forecast, by Indication
      • 8.3.6.1.3. Market size and forecast, by End User
      • 8.3.6.1.4. Market size and forecast, by Distribution Channel
      • 8.3.6.2. France
      • 8.3.6.2.1. Market size and forecast, by Type
      • 8.3.6.2.2. Market size and forecast, by Indication
      • 8.3.6.2.3. Market size and forecast, by End User
      • 8.3.6.2.4. Market size and forecast, by Distribution Channel
      • 8.3.6.3. UK
      • 8.3.6.3.1. Market size and forecast, by Type
      • 8.3.6.3.2. Market size and forecast, by Indication
      • 8.3.6.3.3. Market size and forecast, by End User
      • 8.3.6.3.4. Market size and forecast, by Distribution Channel
      • 8.3.6.4. Italy
      • 8.3.6.4.1. Market size and forecast, by Type
      • 8.3.6.4.2. Market size and forecast, by Indication
      • 8.3.6.4.3. Market size and forecast, by End User
      • 8.3.6.4.4. Market size and forecast, by Distribution Channel
      • 8.3.6.5. Spain
      • 8.3.6.5.1. Market size and forecast, by Type
      • 8.3.6.5.2. Market size and forecast, by Indication
      • 8.3.6.5.3. Market size and forecast, by End User
      • 8.3.6.5.4. Market size and forecast, by Distribution Channel
      • 8.3.6.6. Rest of Europe
      • 8.3.6.6.1. Market size and forecast, by Type
      • 8.3.6.6.2. Market size and forecast, by Indication
      • 8.3.6.6.3. Market size and forecast, by End User
      • 8.3.6.6.4. Market size and forecast, by Distribution Channel
  • 8.4. Asia-Pacific
    • 8.4.1. Key market trends, growth factors and opportunities
    • 8.4.2. Market size and forecast, by Type
    • 8.4.3. Market size and forecast, by Indication
    • 8.4.4. Market size and forecast, by End User
    • 8.4.5. Market size and forecast, by Distribution Channel
    • 8.4.6. Market size and forecast, by country
      • 8.4.6.1. Japan
      • 8.4.6.1.1. Market size and forecast, by Type
      • 8.4.6.1.2. Market size and forecast, by Indication
      • 8.4.6.1.3. Market size and forecast, by End User
      • 8.4.6.1.4. Market size and forecast, by Distribution Channel
      • 8.4.6.2. China
      • 8.4.6.2.1. Market size and forecast, by Type
      • 8.4.6.2.2. Market size and forecast, by Indication
      • 8.4.6.2.3. Market size and forecast, by End User
      • 8.4.6.2.4. Market size and forecast, by Distribution Channel
      • 8.4.6.3. India
      • 8.4.6.3.1. Market size and forecast, by Type
      • 8.4.6.3.2. Market size and forecast, by Indication
      • 8.4.6.3.3. Market size and forecast, by End User
      • 8.4.6.3.4. Market size and forecast, by Distribution Channel
      • 8.4.6.4. Australia
      • 8.4.6.4.1. Market size and forecast, by Type
      • 8.4.6.4.2. Market size and forecast, by Indication
      • 8.4.6.4.3. Market size and forecast, by End User
      • 8.4.6.4.4. Market size and forecast, by Distribution Channel
      • 8.4.6.5. South Korea
      • 8.4.6.5.1. Market size and forecast, by Type
      • 8.4.6.5.2. Market size and forecast, by Indication
      • 8.4.6.5.3. Market size and forecast, by End User
      • 8.4.6.5.4. Market size and forecast, by Distribution Channel
      • 8.4.6.6. Rest of Asia-Pacific
      • 8.4.6.6.1. Market size and forecast, by Type
      • 8.4.6.6.2. Market size and forecast, by Indication
      • 8.4.6.6.3. Market size and forecast, by End User
      • 8.4.6.6.4. Market size and forecast, by Distribution Channel
  • 8.5. LAMEA
    • 8.5.1. Key market trends, growth factors and opportunities
    • 8.5.2. Market size and forecast, by Type
    • 8.5.3. Market size and forecast, by Indication
    • 8.5.4. Market size and forecast, by End User
    • 8.5.5. Market size and forecast, by Distribution Channel
    • 8.5.6. Market size and forecast, by country
      • 8.5.6.1. Brazil
      • 8.5.6.1.1. Market size and forecast, by Type
      • 8.5.6.1.2. Market size and forecast, by Indication
      • 8.5.6.1.3. Market size and forecast, by End User
      • 8.5.6.1.4. Market size and forecast, by Distribution Channel
      • 8.5.6.2. Saudi Arabia
      • 8.5.6.2.1. Market size and forecast, by Type
      • 8.5.6.2.2. Market size and forecast, by Indication
      • 8.5.6.2.3. Market size and forecast, by End User
      • 8.5.6.2.4. Market size and forecast, by Distribution Channel
      • 8.5.6.3. South Africa
      • 8.5.6.3.1. Market size and forecast, by Type
      • 8.5.6.3.2. Market size and forecast, by Indication
      • 8.5.6.3.3. Market size and forecast, by End User
      • 8.5.6.3.4. Market size and forecast, by Distribution Channel
      • 8.5.6.4. Rest of LAMEA
      • 8.5.6.4.1. Market size and forecast, by Type
      • 8.5.6.4.2. Market size and forecast, by Indication
      • 8.5.6.4.3. Market size and forecast, by End User
      • 8.5.6.4.4. Market size and forecast, by Distribution Channel

CHAPTER 9: COMPETITIVE LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top winning strategies
  • 9.3. Product mapping of top 10 player
  • 9.4. Competitive dashboard
  • 9.5. Competitive heatmap
  • 9.6. Top player positioning, 2022

CHAPTER 10: COMPANY PROFILES

  • 10.1. Pfizer Inc.
    • 10.1.1. Company overview
    • 10.1.2. Key executives
    • 10.1.3. Company snapshot
    • 10.1.4. Operating business segments
    • 10.1.5. Product portfolio
    • 10.1.6. Business performance
  • 10.2. Merck & Co., Inc.
    • 10.2.1. Company overview
    • 10.2.2. Key executives
    • 10.2.3. Company snapshot
    • 10.2.4. Operating business segments
    • 10.2.5. Product portfolio
    • 10.2.6. Business performance
    • 10.2.7. Key strategic moves and developments
  • 10.3. AstraZeneca plc
    • 10.3.1. Company overview
    • 10.3.2. Key executives
    • 10.3.3. Company snapshot
    • 10.3.4. Operating business segments
    • 10.3.5. Product portfolio
    • 10.3.6. Business performance
  • 10.4. Eli Lilly and Company.
    • 10.4.1. Company overview
    • 10.4.2. Key executives
    • 10.4.3. Company snapshot
    • 10.4.4. Operating business segments
    • 10.4.5. Product portfolio
    • 10.4.6. Business performance
  • 10.5. Bayer AG
    • 10.5.1. Company overview
    • 10.5.2. Key executives
    • 10.5.3. Company snapshot
    • 10.5.4. Operating business segments
    • 10.5.5. Product portfolio
    • 10.5.6. Business performance
  • 10.6. Sanofi
    • 10.6.1. Company overview
    • 10.6.2. Key executives
    • 10.6.3. Company snapshot
    • 10.6.4. Operating business segments
    • 10.6.5. Product portfolio
    • 10.6.6. Business performance
  • 10.7. Lupin
    • 10.7.1. Company overview
    • 10.7.2. Key executives
    • 10.7.3. Company snapshot
    • 10.7.4. Operating business segments
    • 10.7.5. Product portfolio
    • 10.7.6. Business performance
    • 10.7.7. Key strategic moves and developments
  • 10.8. Glenmark Pharmaceuticals Limited
    • 10.8.1. Company overview
    • 10.8.2. Key executives
    • 10.8.3. Company snapshot
    • 10.8.4. Operating business segments
    • 10.8.5. Product portfolio
    • 10.8.6. Business performance
    • 10.8.7. Key strategic moves and developments
  • 10.9. Novartis AG
    • 10.9.1. Company overview
    • 10.9.2. Key executives
    • 10.9.3. Company snapshot
    • 10.9.4. Operating business segments
    • 10.9.5. Product portfolio
    • 10.9.6. Business performance
  • 10.10. Teva Pharmaceutical Industries Limited
    • 10.10.1. Company overview
    • 10.10.2. Key executives
    • 10.10.3. Company snapshot
    • 10.10.4. Operating business segments
    • 10.10.5. Product portfolio
    • 10.10.6. Business performance
    • 10.10.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 02. PHARMACEUTICAL SUSPENSION MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. PHARMACEUTICAL SUSPENSION MARKET FOR PARENTERAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. PHARMACEUTICAL SUSPENSION MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 06. PHARMACEUTICAL SUSPENSION MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. PHARMACEUTICAL SUSPENSION MARKET FOR CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. PHARMACEUTICAL SUSPENSION MARKET FOR GASTROINTESTINAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. PHARMACEUTICAL SUSPENSION MARKET FOR NEUROLOGICAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. PHARMACEUTICAL SUSPENSION MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 12. PHARMACEUTICAL SUSPENSION MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. PHARMACEUTICAL SUSPENSION MARKET FOR HOME CARE SETTINGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. PHARMACEUTICAL SUSPENSION MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 16. PHARMACEUTICAL SUSPENSION MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. PHARMACEUTICAL SUSPENSION MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. PHARMACEUTICAL SUSPENSION MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. PHARMACEUTICAL SUSPENSION MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 21. NORTH AMERICA PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 22. NORTH AMERICA PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 23. NORTH AMERICA PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 24. NORTH AMERICA PHARMACEUTICAL SUSPENSION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 25. U.S. PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 26. U.S. PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 27. U.S. PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 28. U.S. PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 29. CANADA PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 30. CANADA PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 31. CANADA PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 32. CANADA PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 33. MEXICO PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 34. MEXICO PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 35. MEXICO PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 36. MEXICO PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 37. EUROPE PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 38. EUROPE PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 39. EUROPE PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 40. EUROPE PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 41. EUROPE PHARMACEUTICAL SUSPENSION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 42. GERMANY PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 43. GERMANY PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 44. GERMANY PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 45. GERMANY PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 46. FRANCE PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 47. FRANCE PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 48. FRANCE PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 49. FRANCE PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 50. UK PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 51. UK PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 52. UK PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 53. UK PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 54. ITALY PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 55. ITALY PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 56. ITALY PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 57. ITALY PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 58. SPAIN PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 59. SPAIN PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 60. SPAIN PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 61. SPAIN PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 62. REST OF EUROPE PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 63. REST OF EUROPE PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 64. REST OF EUROPE PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 65. REST OF EUROPE PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 66. ASIA-PACIFIC PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 67. ASIA-PACIFIC PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 68. ASIA-PACIFIC PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 69. ASIA-PACIFIC PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 70. ASIA-PACIFIC PHARMACEUTICAL SUSPENSION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 71. JAPAN PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 72. JAPAN PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 73. JAPAN PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 74. JAPAN PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 75. CHINA PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 76. CHINA PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 77. CHINA PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 78. CHINA PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 79. INDIA PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 80. INDIA PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 81. INDIA PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 82. INDIA PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 83. AUSTRALIA PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 84. AUSTRALIA PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 85. AUSTRALIA PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 86. AUSTRALIA PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 87. SOUTH KOREA PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 88. SOUTH KOREA PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 89. SOUTH KOREA PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 90. SOUTH KOREA PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 91. REST OF ASIA-PACIFIC PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 92. REST OF ASIA-PACIFIC PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 93. REST OF ASIA-PACIFIC PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 94. REST OF ASIA-PACIFIC PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 95. LAMEA PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 96. LAMEA PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 97. LAMEA PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 98. LAMEA PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 99. LAMEA PHARMACEUTICAL SUSPENSION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 100. BRAZIL PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 101. BRAZIL PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 102. BRAZIL PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 103. BRAZIL PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 104. SAUDI ARABIA PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 105. SAUDI ARABIA PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 106. SAUDI ARABIA PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 107. SAUDI ARABIA PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 108. SOUTH AFRICA PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 109. SOUTH AFRICA PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 110. SOUTH AFRICA PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 111. SOUTH AFRICA PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 112. REST OF LAMEA PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 113. REST OF LAMEA PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 114. REST OF LAMEA PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 115. REST OF LAMEA PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 116. PFIZER INC.: KEY EXECUTIVES
  • TABLE 117. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 118. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 119. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 120. MERCK & CO., INC.: KEY EXECUTIVES
  • TABLE 121. MERCK & CO., INC.: COMPANY SNAPSHOT
  • TABLE 122. MERCK & CO., INC.: PRODUCT SEGMENTS
  • TABLE 123. MERCK & CO., INC.: PRODUCT PORTFOLIO
  • TABLE 124. MERCK & CO., INC.: KEY STRATERGIES
  • TABLE 125. ASTRAZENECA PLC: KEY EXECUTIVES
  • TABLE 126. ASTRAZENECA PLC: COMPANY SNAPSHOT
  • TABLE 127. ASTRAZENECA PLC: PRODUCT SEGMENTS
  • TABLE 128. ASTRAZENECA PLC: PRODUCT PORTFOLIO
  • TABLE 129. ELI LILLY AND COMPANY.: KEY EXECUTIVES
  • TABLE 130. ELI LILLY AND COMPANY.: COMPANY SNAPSHOT
  • TABLE 131. ELI LILLY AND COMPANY.: PRODUCT SEGMENTS
  • TABLE 132. ELI LILLY AND COMPANY.: PRODUCT PORTFOLIO
  • TABLE 133. BAYER AG: KEY EXECUTIVES
  • TABLE 134. BAYER AG: COMPANY SNAPSHOT
  • TABLE 135. BAYER AG: PRODUCT SEGMENTS
  • TABLE 136. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 137. SANOFI: KEY EXECUTIVES
  • TABLE 138. SANOFI: COMPANY SNAPSHOT
  • TABLE 139. SANOFI: PRODUCT SEGMENTS
  • TABLE 140. SANOFI: PRODUCT PORTFOLIO
  • TABLE 141. LUPIN: KEY EXECUTIVES
  • TABLE 142. LUPIN: COMPANY SNAPSHOT
  • TABLE 143. LUPIN: PRODUCT SEGMENTS
  • TABLE 144. LUPIN: PRODUCT PORTFOLIO
  • TABLE 145. LUPIN: KEY STRATERGIES
  • TABLE 146. GLENMARK PHARMACEUTICALS LIMITED: KEY EXECUTIVES
  • TABLE 147. GLENMARK PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT
  • TABLE 148. GLENMARK PHARMACEUTICALS LIMITED: PRODUCT SEGMENTS
  • TABLE 149. GLENMARK PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO
  • TABLE 150. GLENMARK PHARMACEUTICALS LIMITED: KEY STRATERGIES
  • TABLE 151. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 152. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 153. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 154. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 155. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
  • TABLE 156. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
  • TABLE 157. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
  • TABLE 158. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 159. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. PHARMACEUTICAL SUSPENSION MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF PHARMACEUTICAL SUSPENSION MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN PHARMACEUTICAL SUSPENSION MARKET (2022 TO 2032)
  • FIGURE 04. TOP INVESTMENT POCKETS IN PHARMACEUTICAL SUSPENSION MARKET (2023-2032)
  • FIGURE 05. HIGH BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 07. HIGH THREAT OF SUBSTITUTES
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 10. GLOBAL PHARMACEUTICAL SUSPENSION MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. PHARMACEUTICAL SUSPENSION MARKET, BY TYPE, 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR ORAL, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR PARENTERAL, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION, 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR INFECTIOUS DISEASES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR CANCER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR GASTROINTESTINAL, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR NEUROLOGICAL, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. PHARMACEUTICAL SUSPENSION MARKET, BY END USER, 2022 AND 2032(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR HOME CARE SETTINGS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 24. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 25. PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL, 2022 AND 2032(%)
  • FIGURE 26. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 27. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 28. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUSPENSION MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 29. PHARMACEUTICAL SUSPENSION MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 30. U.S. PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. CANADA PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. MEXICO PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. GERMANY PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. FRANCE PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. UK PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. ITALY PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. SPAIN PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. REST OF EUROPE PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. JAPAN PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. CHINA PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. INDIA PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. AUSTRALIA PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. SOUTH KOREA PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
  • FIGURE 44. REST OF ASIA-PACIFIC PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
  • FIGURE 45. BRAZIL PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
  • FIGURE 46. SAUDI ARABIA PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
  • FIGURE 47. SOUTH AFRICA PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
  • FIGURE 48. REST OF LAMEA PHARMACEUTICAL SUSPENSION MARKET, 2022-2032 ($MILLION)
  • FIGURE 49. TOP WINNING STRATEGIES, BY YEAR (2020-2023)
  • FIGURE 50. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)
  • FIGURE 51. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)
  • FIGURE 52. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 53. COMPETITIVE DASHBOARD
  • FIGURE 54. COMPETITIVE HEATMAP: PHARMACEUTICAL SUSPENSION MARKET
  • FIGURE 55. TOP PLAYER POSITIONING, 2022
  • FIGURE 56. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 57. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 58. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 59. MERCK & CO., INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 60. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 61. MERCK & CO., INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 62. ASTRAZENECA PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 63. ASTRAZENECA PLC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 64. ELI LILLY AND COMPANY: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 65. ELI LILLY AND COMPANY: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 66. BAYER AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 67. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 68. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 69. SANOFI: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 70. SANOFI: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 71. SANOFI: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 72. LUPIN: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 73. LUPIN: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 74. GLENMARK PHARMACEUTICALS LIMITED: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 75. GLENMARK PHARMACEUTICALS LIMITED: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 76. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 77. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 78. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 79. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 80. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)